CD3

Overview

CD3 is a venture capital firm and drug discovery center based in Leuven, Belgium, dedicated to transforming groundbreaking biomedical research into new medicines. By collaborating with academic research groups and biotech companies, CD3 bridges the gap between innovative science and the pharmaceutical industry, creating value for all stakeholders involved. Their mission is to discover new medicines that address some of the most serious medical needs of our time. The firm focuses on investing in drug discovery projects, spin-off companies, and biotech firms, providing them with experienced drug discovery teams and state-of-the-art infrastructure. CD3 has a strong track record, having initiated over 35 drug discovery projects and established more than 15 partnerships with pharmaceutical or biotech companies. Their portfolio includes investments in various therapeutic areas, such as infectious diseases, cancer, and respiratory illnesses. In October 2023, CD3 successfully closed its fourth fund, raising €70.5 million, bringing the total capital managed by the firm to €154.5 million. This funding, provided by KU Leuven Research & Development (LRD), the European Investment Fund (EIF), and the Gemma Frisius Fund (GFF), supports the firm's ongoing efforts to advance biomedical discoveries from academic research groups and biotech companies into new medicines that improve people's lives worldwide.

Investment Focus

• Innovative biomedical research
• Strong scientific foundation
• Potential for commercialization
• Experienced management team
• Clear regulatory pathway
• Scalable business model
• Addressing significant medical needs
• Competitive advantage
• Sustainable business practices
• Alignment with CD3's therapeutic focus areas

Portfolio Companies